Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation
Open Access
- 31 May 2004
- journal article
- clinical trial
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 10 (5), 328-336
- https://doi.org/10.1016/j.bbmt.2003.12.305
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Rapamycin inhibits IL-4—induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivoBlood, 2003
- Sirolimus: its discovery, biological properties, and mechanism of actionTransplantation Proceedings, 2003
- Molecular actions of sirolimus: sirolimus and mTorTransplantation Proceedings, 2003
- Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expressionBlood, 2003
- Rapamycin impairs antigen uptake of human dendritic cells1Transplantation, 2003
- Rapamycin inhibits macropinocytosis and mannose receptor–mediated endocytosis by bone marrow–derived dendritic cellsBlood, 2002
- Effect of rapamycin on the cyclosporin A–resistant CD28-mediated costimulatory pathwayBlood, 2002
- Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophagesBlood, 2001
- Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progressionClinical Biochemistry, 1998
- Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trialBlood, 1989